FNBT
BMY.RT

FineMark National Bank & Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

FineMark National Bank & Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,926
Closed -$8K – 456
2020
Q4 		$8K Sell
10,926
-190
-2% -$405 ﹤0.01% 414
2020
Q3 		$25K Buy
11,116
+800
+8% +$2.29K ﹤0.01% 376
2020
Q2 		$37K Sell
10,316
-210
-2% -$758 ﹤0.01% 363
2020
Q1 		$40K Sell
10,526
-187
-2% -$616 ﹤0.01% 341
2019
Q4 		$32K Buy
+10,713
New +$27.9K ﹤0.01% 377

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

FineMark National Bank & Trust's BMY.RT Position: Q1 2021 in Review

FineMark National Bank & Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,926 shares — an estimated $8K sold.

FineMark National Bank & Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $40K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • FineMark National Bank & Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • FineMark National Bank & Trust sold 10,926 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
  • FineMark National Bank & Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • FineMark National Bank & Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $40K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on FineMark National Bank & Trust's 13F filing for Q1 2021, filed 12 May 2021.